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S208 Oral Presentationsdespite persistently elevated plasma BAFF levels. High BAFF to B cell
ratios are associatedwith increased proportions of activated peripheral
B cells. B cell reconstitution occurs during constant exposure to allo-
and neo-autoantigens after HSCT. We hypothesize that failure to
delete these potentially pathologic cells in cGVHDisdue toBAFFsig-
naling. We recently found that B cells from patients with active
cGVHD have decreased pro-apoptotic Bim (Wooten et al ASH
2010, Abstract 216). BAFF is known to enhance B cell survival by
counteracting pro-apoptotic Bim, but upstream BAFF-driven survival
signaling in cGVHD (and other diseases) remains undetermined.
HSCT patients who were .12 months post-HSCT, not receiving
high dose steroid, with or without active cGVHD were studied. We
first examined apoptotic rates by flow cytometric analysis of 14 freshly
isolated (to .95% CD19+ purity) B cell samples cultured over time.
Patients with active cGVHD (n 5 4) had significantly decreased
apoptosis at 48 hours, compared to either patients who had never de-
velopeddisease (n55)or tohealthy controls (n5 5) (p\0.005).While
BAFF-driven B cell survival can bemodulated by altered expression of
apoptotic factors, it can also be affected by cellular metabolic fitness.
To examine B cell metabolic fitness wemeasured cellular protein con-
tent in freshly purified B cells from 28 HSCT patients. Significantly
increased B cell protein content was found in active cGVHD patients
(n 5 10) compared to patients who never developed disease (n 5 7)
(p\0.005). Increased protein content was also found in patients who
had inactive disease (n 5 11) although this did not reach statistical
significance. Since BAFF is known to induce metabolic fitness via
phosphorylation of AKT in murine B cells, we examined AKT
activation by immunoblotting freshly isolated B cell lysates from 18
HSCT patients. B cells from patients with active cGVHD (n 5 8)
had significantly increased phosphorylated AKT (pS743 normalized
to total AKT) compared to patients with inactive disease (n 5 7)
(p\0.005). By contrast, no difference in Erk phosphorylation was
found between groups. Our study reveals that B cells in cGVHD
have increased survival due to increased AKT pathway driven
metabolic fitness. Thus, we provide rationale for study of small
molecule inhibitors of the AKT pathway in cGVHD patients.
Table. B cells from patients with cGVHD have increased cel-
lular protein content and AKTactivation
Cellular Protein Normalized One-waycGVHD
GroupContent (mg protein /
1 x 10^6 cells)
Mean +/- SEOne-way
ANOVA,
versus NopAKT (pS743 /
AKT)
Mean +/- SEANOVA,
versus
InactiveNo 35.4 +/- 5.4, n 5 7 - 0.16 +/- 0.09, n 5 3 NSInactive 56.9 +/- 5.2, n 5 11 NS 0.05 +/- 0.02, n 5 7 -Active 75.8 +/- 9, n 5 10 p < 0.005 0.63 +/- 0.15, n 5 8 p < 0.005NS; Not significant.16
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Background: ScGVHD is characterized by progressive fibrosis of
the dermis and subcutis and develops in 4-13% of patients with
cGVHD. The clinical risk factors and mechanisms responsible for
ScGVHD remain unclear; however, the profibrogenic platelet-
derived growth factor (PDGF) and transforming growth factor-
b (TGF-b) signaling pathways have been implicated. Imatinib
mesylate is a tyrosine kinase inhibitor that has activity against both
PDGFR and TGF-b as well as a well-established safety profile for
the treatment of chronic myelogenous leukemia.
Methods: Eligible patients had ScGVHD limiting range-of-motion
(ROM) of at least 1 joint by .25%. Initially, patients were given
400mg (pediatric 260mg/m2) imatinib daily (cohort 1), with dose
reduction allowed for toxicity. Due to a high incidence of adverseeffects (AEs) and subsequent dose reduction, the study was amended
to start 100mg with escalation to 200mg daily at 1 month. The 6
month primary endpoint was based on percent improvement of the
deficit compared to baseline at 1-3 target joints: partial response
(PR) 5 increase of .25%; progressive disease (PD) 5 decrease of
.25%, or .1 steroid pulse per 3-month period; stable disease
(SD) 5 all other. Secondary endpoints included toxicity; multi-mo-
dality skin assessments (MRI, skin score, and patient-reported mea-
sures); quality of life and functional measures; steady state serum
drug concentrations (cohort 2); and response of other cGVHD-af-
fected organs.
Results: Twenty patients were enrolled (8 cohort 1, 12 cohort 2).
Two patients had PD; 5 PR; 7 SD; and 6 were non-evaluable
(Table 1). Of 11/14 (78.6%) patients with any ROM improvement,
the average gain in ROMwas 31%. No significant improvement was
seen in other cGVHD manifestations. Frequent AEs included hy-
pophosphatemia, GI upset, fatigue, muscle cramping and pain.
Other clinically significant AEs were tinnitus (n5 4) and pulmonary
edema requiring hospitalization (n 5 2). Steady state serum con-
centrations in cohort 2 (200mg daily) ranged from 592-2255ng/mL
(mean 1157ng/mL), which is within the inhibitory range of imatinib
on PDGFR.
Table 1. Patient Responses
% changePatient
Number Age GenderTime from
cGVHD
Dx (mos) pBaseline
ROM %
redictedin deficit
from baseline
at 6 mos Response Final Dose1 56 Male 48.5 37% Off-withdrawal N/A N/A2 60 Male 48.2 56% 94% PR 300mg3 10 Female 39.1 73% Off- 3 mos PD PD N/A4 52 Female 28.9 7% Off- toxicity N/A N/A5 30 Male 87.0 34% Off - withdrawal N/A N/A6 51 Male 88.1 47% Off - withdrawal N/A N/A7 55 Female 42.5 61% 35% PR 200 mg8 58 Male 39.1 35% 16% SD 200 mg9 60 Male 79.4 42% Off - withdrawal N/A N/A10 53 Male 20.3 -7% 21% SD 200 mg11 28 Female 15.8 56% Off - cancer
relapse
N/A N/A12 56 Male 80.3 37% 16% SD 100 mg13 34 Female 21.4 27% 61% PR 200 mg14 46 Male 40.6 32% 27% PR 200 mg15 55 Male 33.5 22% 22% SD 200 mg16 55 Male 4.8 71% 3% SD 200 mg17 7 Female 25.4 64% -25% SD 100 mg (peds)18 21 Male 58.9 54% -2% SD 200 mg19 48 Male 112.9 33% 31% PR 200 mg20 18 Male 35.0 -5% 15% SD 200 mgcGVHD 5 chronic graft versus host disease, Dx 5 diagnosis, mo 5
month, ROM5 range of motion, PD5 progressive disease, PR5 partial
response, SD 5 stable disease, N/A 5 not assessed.
Conclusions:Treatment with imatinib mesylate for 6 months led to
improved ROM in most patients. This data suggests that low-dose
imatinib therapy has efficacy for ScGVHD; however, despite serum
drug concentrations in the expected range for the doses prescribed,
tolerability was a significant limitation for the use of imatinib mesy-
late in patients with ScGVHD.
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Graft-versus-host disease (GvHD) is a serious challenge to the
success of hematopoietic stem cell transplantation. The cytokine
Oral Presentations S209milieu of GvHD includes IL-6, IL-12, and IL-23, favoring Th1/
Th17 differentiation over that of regulatory T cells (Treg). We
show that blockade of IL-6-receptor-alpha in vitro with tocilizumab
(humanized Mab, 5 ug/ml) fails to alter alloreactive T cell prolifera-
tion (P5NS, n5 4), Treg expansion (8.87 v 9.90%, P5NS, n5 4),
or Th1/Th17 differentiation (19 v 19.6%, 1.32 v 1.53%, P 5NS, n
5 3). Janus kinase 2 (JAK2) relays downstream signaling by IL-6, IL-
12, and IL-23, through the phosphorylation of signal transducer and
activator of transcription 3 (STAT3). We demonstrate that
TG101348, a very specific, small molecule inhibitor of JAK2,
when present during initial and secondary encounters between hu-
man T cells and fully HLA-disparate, allogeneic monocyte-derived
dendritic cells (moDCs), induces durable and specific T cell toler-
ance on reexposure to the priming alloantigens. TG101348 ablates
the IL-6/JAK2/pSTAT3 pathway in T cells (24 v 0%, P\0.05, n
5 5) without off-target effects on IL-2 or IL-15/JAK3/pSTAT5-de-
pendent signaling, which would interfere with Treg development
and important effector T-cell responses. JAK2 inhibition enhances
the ratio of CD4+ Tregs to CD8+CD25+ effector T cells in favor
of Tregs (Treg:Effector 1:2 vs 1:1, P\0.05, n 5 5). JAK2 inhibition
also reduces IL-6 (255 vs 157 pg/ml, P\0.05, n5 5) and TNF-alpha
(50 vs 15 pg/ml, P\0.05, n5 4) production in allogeneic MLRs, im-
pairing the activation of central and effector memory T cells, as well
as the expansion of responder Th1 (24 vs 14%, P\0.05, n 5 4) and
Th17 (2 vs 1%, P\0.05, n5 4). T cells primed by allogeneicmoDCs
have a profound inability to respond upon reexposure to fresh allo-
geneic moDCs from the original stimulator, whether the JAK2 in-
hibitor were present in either the primary or the secondary MLR
(P\0.05, n 5 4). This indicates that TG101348 can prevent initial
sensitization, as well as recall responses by already sensitized T cells,
to alloantigen. Responses to stimulation de novo by influenza matrix
peptide (fluMP), a pathogenic nominal antigen, remain intact (P 5
NS, n5 4). JAK2 inhibition, but not IL-6 blockade alone, therefore
induces durable tolerance in HLA-disparate pairings, without
broader immune impairment. These findings provide a strong ratio-
nale for exploring this strategy in both GvHD prophylaxis and treat-
ment.18
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TIENTS WITH FANCONI ANEMIA: THE BRAZILIAN EXPERIENCE USING
CYCLOPHOSPHAMIDE 60MG/KG
Bonfim, C.1, Ribeiro, L.1, Bitencourt, M.1, Zanis-Neto, J.1, Seber, A.2,
Gouveia, R.2, Florencio, R.3, Souza, A.4, Daudt, L.5, Vieira, A.K.6,
Ostronoff, M.3, Bouzas, L.F.4, Pasquini, R.1 1Federal University of Par-
ana, Curitiba, PR, Brazil; 2 Instituto de Oncologia Pediatrica, Sao Paulo,
SP, Brazil; 3Hospital Real Portugues, Recife, PE, Brazil; 4National Can-
cer Institute, Rio de Janeiro, RJ, Brazil; 5Federal University of Rio Grande
do Sul, Rio Grande do Sul, RS, Brazil; 6Federal University of Minas Ger-
ais, Belo Horizonte, MG, Brazil
Fanconi anemia(FA) is a rare disease characterized by progressive
bone marrow failure, congenital anomalies and striking predisposi-
tion to cancer. BMT is indicated for pts who develop pancytopenia,
myelodysplasia or acute leukemia. During the past 30 years we have
progressively decreased the dose of Cyclophosphamide(CY) in the
preparatory regimen which resulted in a significant increase in sur-
vival.
Objective: Analyze the outcome of 85 pts with FA submitted to an
HLA matched related BMT in 6 Brazilian centers using CY 60mg/
kg as the preparatory regimen.
Patient and Methods: Period: 07/1999-05/2011. Gender: 40F/
45M. Age 3-34 years (M: 9). Type of donor: Siblings:74pts; other re-
lated: 11pts. Eighty-two pts had severe pancytopenia while 3 had
overt myelodysplastic syndrome(MDS). All received the same prepa-
ratory regimen with CY60mg/kg and GVHD prophylaxis with cy-
closporin and methotrexate.
Results: 72 pts are alive between 5 months and 12 ys after BMT
(M:5ys) with an overall survival (OS) of 85% in 5 ys. Pts transplanted
under the age of 10(48pts) had an OS of 95,6% in 5ys. Two pts died
before D+28 and were not evaluable for engraftment. Rejection oc-
curred in 6 pts: 2 had primary graft failure and both are alive and well
after a 2nd BMT(same donor). Late graft failure occurred in 4 pts atamedian of 244 days after BMT(range: 152- 365 days). Three pts un-
derwent a 2nd BMT (same donor) and 2 are alive and well 8 and 10 ys
after transplant. All pts with overt MDS relapsed and died of pro-
gressive disease despite a 2nd BMT. Mucositis grade II-III occurred
in 80%. Seventeen of 81 evaluable pts developed Acute-GVHD
(grade III: 4pts, grade IV: 3pts) while 23/78 evaluable pts had
chronic-GVHD (extensive: 12 pts). In multivariate analysis, only
acute and chronic GVHD were associated with a lower OS. Four
pts developed carcinoma of the tongue between 2 and 5 years after
BMT, two are alive and one has active disease. All had extensive
C-GVHD involving the oral mucosa. Thirteen pts died between
12 and 2034 days after BMT (M: 256 days). The major causes of
death were related to GVHD/infections and rejection. TRM at
100 days was 6% and at 1 year was 10%.
Conclusions: This regimen is well tolerated and associated with an
excellent survival especially in children younger than 10 years. Acute
and chronic GVHD had an impact in overall survival and strategies
are being developed to reduce this complication.19
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Disease relapse remains a major obstacle to successful allogeneic
hematopoietic cell transplantation (HCT). The development of
chronic graft-versus-host disease (cGVHD) has been associated
with fewer relapses. However, the peak incidences of early relapse
and cGVHD commonly overlap after HCT and variations in treat-
ment make it difficult to evaluate the relative impact of cGVHD on
HCT outcomes. In this study, we investigated the association of
cGVHD and the incidence of late relapse (.12 months) after
HCT. The study included patients who were alive and disease free
at one year after HCT. We also assessed the impact of cGVHD
on treatment related mortality (TRM), disease free survival (DFS)
and overall survival (OS) for 1 year disease-free survivors. The study
included 7489 recipients of HCT from HLA-identical siblings or
URDs conditioned with high intensity regimens for acute myeloid
leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid
leukemia (CML), or myelodysplastic syndrome (MDS) between
1995 and 2004 and reported to the Center for International Blood
and Marrow Transplant Research. Forty-seven percent of the study
population was diagnosed with cGVHD within 12 months of HCT.
The protective effect of cGVHD on late relapse was limited to pa-
tients diagnosed with CML (RR: 0.47, 95% CI: 0.37-0.59,
P\0.0001). Other factors significantly associated with a lower risk
of relapse were early diagnosis of acute GVHD (within 29 days of
HCT), grafts from well-matched or partially-matched URD, and
GVHD prophylaxis other than T-cell depletion. cGVHD was sig-
nificantly associated with a higher risk of TRM (RR: 2.43, 95%
CI: 2.09-2.82, P\0.0001) and inferior OS (RR: 1.56, 95% CI:
1.41-1.73, P\ 0.0001). A separate analysis was performed for
CML patients to evaluate the impact of cGVHD specific variables
